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Abstract
Background: The Korean Undiagnosed Diseases Program (KUDP) was launched in January 2017 as a one-year pilot
project to address the increasing global interest in patients with undiagnosed rare diseases. The purpose of this
paper is to summarize the project results and emphasize the unmet research needs among patients with undiagnosed
rare diseases in Korea.
Results: Patient enrollment, assessment, and diagnostic processes were determined by the KUDP clinical expert
consortium. Patients followed a diagnostic workflow after being categorized into one of four groups: I) insufficient
clinical information or lack of standard diagnostic processes; II) undiagnosed due to low disease awareness; III) clinically
diagnosed but unconfirmed genetically due to genetic heterogeneities; or IV) unknown disease due to complex,
atypical clinical presentations. After excluding two patients from group I, 97 patients were enrolled, including 10 in
group II, 67 in group III, and 20 in group IV. Most of them (92 of 97, 94.8%) were pediatric patients (< 18 years old) and
59 (60.8%) were male. The primary symptoms for 80 patients (82.5%) were neurologic. During the one-year pilot study,
72 patients completed a diagnostic assessment including clinical and molecular genetic analyses; some patients also
underwent pathological or biochemical analysis. Twenty-eight of these patients (28/72, 38.9%) achieved molecular
genetic diagnosis. Thirteen patients were diagnosed based on traditional tests, including biochemical assay, single or
targeted genetic analysis, and chromosomal microarray. We performed whole exome sequencing on 52 patients, among
whom 15 (28.8%, 15/52) reached a final diagnosis. One new disorder was identified via international collaboration.
Conclusions: Using an efficient clinical diagnostic workflow, this KUDP pilot study resulted in a fair diagnostic success
rate, improving the potential for additional diagnoses and new scientific discovery of complex and rare diseases. KUDP
also satisfied unmet needs for rare diseases with multisystem involvement, highlighting the value of emerging genomic
technologies for further research into rare and still-undiagnosed conditions.
Keywords: Rare disease, Undiagnosed disease program, Korea, Whole exome sequencing
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: chaeped1@snu.ac.kr
†Soo Yeon Kim, Byung Chan Lim and Jin Sook Lee are equal first authors.
1Department of Pediatrics, Pediatric Clinical Neuroscience Center, Seoul
National University Children’s Hospital, Seoul National University College of
Medicine, Seoul, Korea
17Division of Pediatric Neurology, Department of Pediatrics, Pediatric Clinical
Neuroscience Center, Seoul National University Children’s Hospital, Seoul
National University College of Medicine, 101 Daehakro Jongno-gu, Seoul
110-744, Korea
Full list of author information is available at the end of the article
Kim et al. Orphanet Journal of Rare Diseases           (2019) 14:68 
https://doi.org/10.1186/s13023-019-1041-5
Background
Rare disease (RD) is defined as one that affects fewer than
5 per 10,000 persons in the European Union (EU) or fewer
than 200,000 persons in the United States (US). In Korea,
the Rare Disease Act of 2016 defined RD as affecting fewer
than 20,000 patients or for which the prevalence is
unknown because of its rarity. There are countless RDs
worldwide, with almost 8% of the general population suf-
fering from a RD despite their relative rarity [1]. To date,
more than 7000 RDs have been identified and their
numbers have continued to increase, while there remain
numerous unidentified diseases [2, 3]. Patients with a RD
can spend more than 5–6 years reaching a diagnosis, while
many remain undiagnosed [4, 5]. These circumstances
cause excessive medical costs and long-term social bur-
dens, as well as loss of well-being among both patients
and their families. Thus, undiagnosed RDs are a global
challenge that must be overcome.
Global networks, funds, and new technology develop-
ment will be required to meet these goals. Fortunately, in-
vestigations are improving through the use of advanced
genetic technologies, including next-generation sequencing
(NGS) and growing international collaboration. Many
countries have initiated projects on undiagnosed RDs,
including the Undiagnosed Diseases Program (UDP) by the
US National Institutes of Health (NIH), the Solving the
unsolved rare diseases (Solve-RD) program funded by the
European Commission, the Finding of Rare Disease Genes
(FORGE) project in Canada, and the Initiative on Rare and
Undiagnosed Diseases (IRUD) project in Japan [4, 6–8].
While Undiagnosed Diseases Network International
(UDNI) was established with international effort, UDP-WA
in Australia was clinically implemented within the public
health system in 2016 [9]. For several years, the Korea Na-
tional Institute of Health (KNIH) of the Korea Centers for
Disease Control and Prevention (KCDC) have supported
the genetic diagnosis of patients with some RDs. Recently,
the KNIH added to their supporting policy all “undiag-
nosed” or “unknown” RDs and launched KUDP. The first
step in this process was a one-year pilot project starting in
January 2017 to determine the Korean context for undiag-
nosed patients and to plan a sustainable KUDP. Herein, we
summarize the results of this one-year pilot project and
emphasize the importance of a sustainable KUDP.
Methods
Study approval and preparation of the project
The pilot project was initiated and supported by the KNIH.
Seoul National University Children’s Hospital functioned
as the main center and supervised this process. Three re-
gional hospitals were also involved to recruit and evaluate
patients. The expert consortium consisted of more than 20
specialists covering nearly all divisions of pediatrics and re-
lated departments, such as pediatric neurology, cardiology,
nephrology, hematology, surgery, as well as adult neur-
ology, rheumatology, endocrinology, ophthalmology, otol-
ogy, orthopedics, clinical genetics, laboratory medicine,
and bioinformatics, across six institutes. Patients were en-
rolled via two methods: a referral letter from local clini-
cians, and by presenting directly to a central hospital clinic.
Written informed consent for DNA preparation and de-
tailed tests was obtained from all enrolled patients or their
legal representatives. Procedures were approved by the In-
stitutional Review Board (IRB) of Seoul National University
Hospital (IRB No. 1101-110-353, 1406-081-588, 1511-099-
722, 1408-010-599).
Diagnostic workflow
A total of 99 patients were referred for the study. All but
two of these visited the central hospital. The others were
referred by local clinicians via recruitment letter. The ex-
pert consortium classified each patient into one of four
groups: I) insufficient clinical information or lack of stand-
ard diagnostic processes; II) undiagnosed due to low dis-
ease awareness; III) genetically undiagnosed due to genetic
and clinical heterogeneities; or IV) unknown disease due to
complex, atypical clinical presentations. Two patients who
were referred by letter were classified into group I and
could not be recruited into the project because of a lack of
clinical information and standard evaluation for suspicious
diagnoses. The remaining 97 patients were finally enrolled
and underwent a serial diagnostic process based on deci-
sions by the clinical expert consortium. The first-tier test
included chromosomal microarray, enzyme assay, single-
gene sequencing, and targeted multi-gene panel. Whole ex-
ome sequencing (WES) was conducted as a first diagnostic
test as well as a second-tier test, in some cases based on
the decision of the expert consortium. Muscle biopsy was
also performed in two patients with suspicious primary
muscle disease. In cases undiagnosed after the first-tier test,
the expert consortium reviewed each one and decided on
the next step, including performing a second-tier genetic
test or connecting to nationwide and/or international sci-
entific research networks. Detailed procedures, including




Demographic data for the 97 patients are described in
Table 1 and Fig. 1. Ninety-two (94.8%) were children
(under 18 years old) and 59 (60.8%) were male. Patients
under 5 years of age accounted for over half of the pa-
tients, whereas there were only five patients over 18 years.
Patients’ first hospital visit was when they were on average
2.5 years old (0–18.4 years). Seventy-six patients (76/97,
78.4%) first accessed medical services within 3months of
symptom recognition. On their diagnostic journey, these
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patients visited an average of 2.5 clinics, including 1.6
tertiary centers, such as university-based major medical
centers, where they had an average of 6.2 types of tests
(range 2–14). About 70% of patients (68 of 97) had one or
more genetic tests, including chromosomal microarray,
single gene sequencing, designed target gene panel se-
quencing, and clinical exome sequencing, which uses the
TruSight One Sequencing Panel to target more than 4800
genes associated with specific clinical phenotypes. Despite
exhaustive diagnostic efforts, they remained undiagnosed
for an average of 5.3 years (0–17.7 years). More than half
of the patients (67/97, 69.1%) were classified into group
III, 10 into group II, and 20 into group IV. More than 90%
of these patients (93/97, 95.9%) complained of one or
more neurologic manifestations, including developmental
delay, intellectual disability, intractable seizures, involun-
tary movements, or muscle weakness. All but nine pa-
tients (88/97, 90.7%) had more than one presenting
symptom in different organs: gastrointestinal problems in-
cluding growth failure in 25 (25.8%); ophthalmologic
symptoms in 24 (24.7%); and skeletal involvement in 21
(21.6%).
Diagnostic success rate
After KUDP admission, patients underwent individualized
tests by stages. The overall schematic diagnostic process
and its result are shown in Additional file 1: Figure S1.
Among the 97 patients, 72 (74.2%) completed one or more
diagnostic process and 28 (28/72, 38.9%) had confirmative
diagnosis. Ten patients in group II had traditional tests,
including single-gene sequencing, single enzyme assay, and
multi-gene panel sequencing, based on clinical suspicions.
Among these, eight patients (8/10, 80%) received confirma-
tive diagnoses. In most cases, patients in groups III and IV
had WES as their first- or second-tier tests, although five
patients achieved a molecular diagnosis through traditional
tests. Diagnostic yield according to each modality is de-
scribed in Table 2. Traditional tests, including biochemical
assay, single or targeted genetic analysis, and chromosomal
microarray, led to accurate molecular diagnosis in 13 of
the 31 completely analyzed tests (41.9%). WES indicated
28.8% of the diagnostic yield: 25.0% for proband only and
35.0% for trio analysis. None of these patients had dual
diagnoses. In addition, three candidate genes that had not
been previously reported in human diseases were found.
We initiated a functional study of one candidate gene and
used web-based matchmaking tools for the other two [13].
Detailed genotypes and phenotypes for each case with
genetic confirmation are described in Table 3.
Illustrative cases
Ending the diagnostic odyssey
A 10-month-old girl admitted to KUDP initially presented
with developmental delay from the age of 5months. She
had been seen at two different tertiary care neurology
clinics and had undergone extensive testing, including re-
peat brain magnetic resonance imaging (MRI), metabolic
screening, and diagnostic exome sequencing. These com-
prehensive evaluations failed to identify genetic defects, al-
though she was identified as having developmental delay
with brain malformation. After KUDP admission followed
by reevaluation at an expert clinic, additional findings such
as myopathic face and elevated serum CK level (6275 IU/L,
normal range 20–270 IU/L) were identified. The expert
consortium suspected alpha-dystroglycan-related congeni-
tal muscular dystrophy, including Fukuyama type, and
fukutin gene analysis was performed. Compound heterozy-
gous mutations in FKTN, c.165 + 835 T >G (deep intronic
mutation, founder mutation in Korean population) and
c.49A >C, were identified as a confirmative diagnosis [14].
In another case, a 12-month-old girl had been evaluated
for developmental delay at two other tertiary hospitals.
Brain MRI had revealed mild brain atrophy and delayed
myelination, and laboratory tests including metabolic
screening were unremarkable except for slightly elevated
liver enzymes. She was admitted to KUDP and reevaluated
by the expert consortium, which recognized her develop-
mental arrest as being followed by regression and noticed
diffuse hypomyelination on her brain MRI. We then
performed a skeletal survey, which indicated dysostosis
multiplex such as inferior beaking of the lumbar spine.
Suspecting GM1-gangliosidosis, enzyme assay for β-galac-
tosidase was ordered, which revealed markedly decreased
activity (1.0 nmol/hr./mg protein, normal range 80–140
Table 1 Enrolled patient demographics
Number of patients
(total n = 97)
Sex (male:female) 59:38
Mean age of symptom onset (years) 2.1 (0–13.8)
Mean age at first medical service (years) 2.5 (0–18.4)
Mean age at KUDP admission (years) 6.7 (0–36.0)
Mean Number of tests before the project 6.2 (2–14)
Number of visited clinics before the




> 4 14 (14.1)
Clinical diagnosis (n, (%))
Neurodevelopmental 54 (55.7)
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nmol/hr./mg protein). We also performed Sanger sequen-
cing for GLB1 and identified compound heterozygous mu-
tations, c.517_519delCTC and c.1343A >T.
Correction of misdiagnosis
A 13-year-old boy with progressive lordosis, asymmetric
scapular deformity was admitted to KUDP. For 9 years
prior to admission, his clinical diagnosis was facioscapu-
lohumeral muscular dystrophy, although there were nei-
ther abnormalities in his genetic analysis nor specific
findings of muscle pathology. After KUDP admission, we
reanalyzed the patient’s phenotype; under the clinical
diagnosis of another type of primary muscle disease, tar-
geted multi-gene panel sequencing for muscle disease
was performed, revealing compound heterozygous muta-
tions of GAA (c.1316T > A and c.2238G > C). The boy
was finally diagnosed with late-onset Pompe disease, and
started enzyme replacement therapy. After molecular
diagnosis, we again reviewed his muscle pathology and,
interestingly, noticed very few muscle fibers with fine,
small purple-colored granules, a pathognomonic finding
suggesting Pompe disease (Fig. 2). This case clearly dem-
onstrated the clinical utility of NGS in atypical presenta-
tion of known genetic disorder. In addition, it highlights
the importance of appropriate treatment with accurate
diagnosis, which can reverse the clinical course.
Discovery of a new disease via international collaboration
An 8-year-old boy was admitted to KUDP with develop-
mental delay and cryptorchidism since birth, and pro-
gressive melanocytic nevus with skin pigmentation since
the age of 1 year. His brain MRI revealed myelination
delay and corpus callosum hypogenesis. As there was no
definite clinical diagnosis, trio WES was performed,
Fig. 1 Characteristics of the enrolled patients. a Number of patients in each category. b Age distribution at initial symptom onset and KUDP
admission. c Time between initial symptom onset and KUDP admission. d Distribution of organ involvement. e Number of presenting symptoms
per patient. f Number of completed tests for each patient before KUDP admission
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revealing a de novo variant in RAB11B, c.64G > A. Be-
cause RAB11B had never been reported in a human as a
disease-causing gene, we shared the phenotype and gen-
omic data with other international groups through the
online matchmaking service and thereby confirmed that
the genetic defect disturbing the GTP/GDP binding
pocket of RAB11B caused this specific neurodevelop-
mental syndrome [15].
Discussion
KUDP was launched in January 2017 as a one-year pilot
project, considering the growing international interest in
undiagnosed patients with RDs, to determine the feasi-
bility and usefulness of a sustainable UDP in Korea and
a medical system for rare disease diagnostics. Recently
emerging genomic technology and international collab-
oration made it possible to increase insights into various
and complex RDs and their phenotypes. Comparable to
previous studies, this report shows that more than
three-quarters of recruited patients were children youn-
ger than 18 years old who had neurologic symptoms [4,
16–19]. Only limited data have been published detailing
patients’ struggles for a definite RD diagnosis. According
to some studies, patients can spend 5–6 years awaiting a
molecular diagnosis, after multiple visits to clinics and
1–12 diagnostic tests (average 3–5) [17, 19]. In our
study, patients visited on average 2.5 clinics (range, 1–5)
including 1.6 tertiary hospitals and had 6.2 tests prior to
KUDP admission. We also evaluated medical accessibil-
ity, represented by the time from symptom onset to their
first hospital visit, which was an average of 6 months,
with 90 of 97 patients (92.8%) able to access tertiary hos-
pital care within 12 months. Based on the Korean med-
ical referral and insurance system, accessibility of the
tertiary hospitals (e.g., major medical centers including
the KUDP central hospital) was simple. Therefore, we fa-
cilitated two different routes to KUDP admission: 1) a
referral letter from clinicians and 2) a direct visit for the
patient to the KUDP central hospital. All included pa-
tients enrolled in KUDP using the latter route, which
likely had advantages, including that experts could
examine the patients directly and decide whether to en-
roll them or not within a short period. Considering the
Korean medical referral and insurance system, we would
want to maintain those two separate routes to KUDP ad-
mission, although we expect a gradual increase in en-
rolled patients through a nationwide network from
regional clinics. We classified patients into four categor-
ies (I–IV). Category II, undiagnosed due to low aware-
ness, consisted of undiagnosed patients who had
received extensive diagnostic workup at other tertiary
university-based medical centers. We enrolled these pa-
tients in the “pilot” project to evaluate their rare disease
diagnostic status within the current health care system
and to develop a nation-wide network for successful and
effective development of diagnostic pathway of the
KUDP. Henceforth, we plan to exclude patients in cat-
egory II from the main UDP project and refer them back
to their local network hospital, along with guidelines for
appropriate diagnostics. We also plan to expand the
adult patients included in the program and focus on
undiagnosed patients in categories III and IV, followed
by related functional research studies.
Among the 97 enrolled patients, one or more tests with
analyses were completed in 72, and 28 patients received a
final diagnosis (diagnostic success rate: 28/72, 38.9%) dur-
ing 1 year (from January 2017 to December 2017). Trad-
itional tests including chromosomal microarray, enzyme
assay, single-gene analysis, mitochondrial DNA sequen-
cing, and multi-gene panel accounted for 26.6% (34/128)
of the tests performed, which led to confirmative diagnosis
in 13 patients. For the 14 patients who remained undiag-
nosed after traditional tests, WES was usually performed
as a second-tier test. This was also useful as a first diag-
nostic step in relatively well-known genetic disorders with
multiple causative genes or missed patients with complex
and atypical presentation. As for exome sequencing, we
had diagnostic success in 15 of 52 patients whose analyses
were completed (diagnostic yield: 15/52, 28.8%). This rate
is similar to previous studies with WES, which has shown
rates of 25–51.9% [17–21]. Our total success rate was
38.9%, and the diagnostic yield within categories III and
IV was 31.7% (20 of 63), similar to previous studies [22].
In contrast, the success rate for the WES in the first year
of this pilot program was relatively lower, possibly because
of incomplete WES within the proband. Twelve patients
were awaiting additional trio exome sequencing and were
postponed because of budget restrictions (the initial
budget was 130,000,000 Korean Won/year). Work on















14 12 2 16.7
Enzyme assay 2 2 2 100.0
Single gene
test
10 9 4 44.0
mtDNA
sequencing




7 7 4 57.1
Exome, proband 54 32 8 25.0
Exome, trio 40 20 7 35.0
mtDNA mitochondrial DNA
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Table 3 Phenotypes and genotypes of positive cases
No. Gender/age Clinical presentation Diagnostic test Genotype Associated disease
(MIM number.)
1 M/7.9 Global developmental delay, microcephaly,
facial dysmorphism, photosensitivity




2 F/3.9 Developmental delay, myopathic face Single gene FKTN, c.165 + 835
T > G/c.49A > C
Muscular dystrophy-dystroglycanopathy
(MIM #253800)




4 M/17.8 Seizure gait abnormality, intellectual disability WES, proband SLC2A1, c.276-1G >
A
GLUT1 deficiency syndrome 2, childhood
onset
(MIM #612126)




6 M/1.6 Congenital hypotonia Single gene MTM1, c.566A > G Myotubular myopathy, X-linked
(MIM #310400)
7 M/15.3 Global developmental delay, seizure CMA 16p22.3 (29673954–
30,119,759) 0.44 Mb
deletion
8 M/9.5 Paroxysmal dyskinesia Singe gene PRRT2, c.649dupC Episodic kinesigenic dyskinesia
(MIM #128200)
9 M/14.4 Progressive dystonia, dysarthria, dysphagia Single gene ATP1A3, c.2305A > C Dystonia-12
(MIM #128235)





COL6A1, c.850G > A Ullrich congenital muscular dystrophy, 1
(MIM #254090)





















SCN8A, c.3820G > A Epileptic encephalopathy, early infantile, 13
(MIM #614558)
14 M/9.8 Global developmental delay, seizure,
abnormal skin lesion
WES, trio RAB11B, c.64G > A Neurodevelopmental disorder with ataxic
gait, absent speech, and decreased cortical
white matter
(MIM #617807)
15 M/6.0 Global developmental delay, dysmorphic face,
sparse hair, anhydrosis, dental anomaly
WES, proband EDA, c.1045G > A Ectodermal dysplasia 1, hypohidrotic,
X-linked
(MIM #305100)
16 M/13.8 Developmental regression, seizure, dystonia WES, proband CLN6, c.806C >
T/c.184C > T
Ceroid lipofuscinosis, neuronal, 6
(MIM #601780)
17 F/11.9 Global developmental delay, stereotyped
hands movement, seizure




18 F/10.8 Global developmental delay, dysmorphic face WES, proband NAA10, c.247C > T Ogden syndrome
(MIM #300855)









Immunodeficiency, common variable, 10
(MIM #615577)




22 F/8.8 Early onset seizure, global developmental
delay, dysmorphic face
WES, trio DNM1, c.709C > T Epileptic encephalopathy, early infantile, 31
(MIM #616346)
23 F/3.2 Progressive respiratory distress WES, proband SFTPC, c.203T > A Surfactant metabolism dysfunction,
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these patients will soon resume as part of the main pro-
ject; thus, the success rate is likely to further increase.
Despite some differences and limitations compared with
other undiagnosed patient programs, the diagnostic work-
flow through the KUDP pilot project was quite efficient
and resulted in a high yield rate through use of frequent
expert consortium meetings and well-organized genetic
test strategies, the latter of which ranged from traditional
to advanced tests based on the patients’ clinical features.
The importance of appropriate diagnostic tests, including
detailed history taking and traditional tests, has been iden-
tified previously [22]. Furthermore, we verified some likely
pathogenic variants in novel genes that have not previously
been reported in human disease. We registered these vari-
ants on an online international match program to find that
one had been published by another study group as a new
disease discovery [15]. We also started functional validation
of another three genes either independently or through
Fig. 2 Pathology findings and mutation profiles of patient with Pompe disease. a, b Muscle pathology with hematoxylin and eosin staining and
modified Gomori trichrome staining, indicating small angulated muscle fiber with rimmed vacuole, respectively. c Pedigree with mutation profiles
and result of GAA sequencing for patient
Table 3 Phenotypes and genotypes of positive cases (Continued)




24 F8.3 Ataxia, seizure, progressive muscle weakness mtDNA
sequencing
m.8344A > G





Glycogen storage disease II
(MIM #232300)
26 M/12.8 Global developmental delay, failure to thrive,
congenital heart disease
WES, trio POC1A, c.241C >
T/c.239C > T
Short stature, onychodysplasia, facial
dysmorphism, and hypotrichosis
(MIM #614813)
27 F/8.6 Congenital hypotonia, failure to thrive, bilateral
hip dislocation, imperforated anus, congenital
heart disease




28 M/15.7 Tip toeing, slurred speech, pathologic reflexes WES, proband C19orf12, c.294del Neurodegeneration with brain iron
accumulation, 4
(MIM #614298)
WES whole exome sequencing, CMA chromosomal microarray
aConsequence Sanger sequencing for ARSA and GLB1 was performed after final diagnosis through enzyme assay for genetic counseling
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international collaboration and further scientific achieve-
ments are thus expected (data now shown). We anticipate
that the diagnostic yield may increase following completion
of all diagnostic processes and additional functional studies
with international collaborations.
Despite this, more than half of the cases reported here
may remain undiagnosed after all factors have been con-
sidered, a rate similar to undiagnosed patient programs
in other countries [17, 18, 23]. Further research is there-
fore needed for those patients, combined with advanced
bioinformatics and genomic technologies such as RNA
(transcriptome) sequencing and whole-genome sequen-
cing, and more active international data sharing and
collaborations [20].
Overall, the one-year pilot KUDP project demonstrated
full feasibility and established the need for planning a
sustainable KUDP. The cases illustrated here support the
program’s necessity in terms of correcting misdiagnosis,
ending patients’ diagnostic odyssey, and facilitating precise
genetic counseling and therapeutic options for patients.
Conclusions
We have summarized the results of the one-year pilot Ko-
rean Undiagnosed Diseases Program. Using an efficient
diagnostic process, we achieved a successful diagnostic rate
of 38.9% and clearly illustrated the need for an ongoing,
sustainable program for undiagnosed rare diseases in
Korea.
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of all patients. (JPG 213 kb)
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